{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,25]],"date-time":"2024-08-25T04:34:30Z","timestamp":1724560470102},"reference-count":87,"publisher":"Bentham Science Publishers Ltd.","issue":"8","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["MC"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:sec><jats:title>Abstract:<\/jats:title><jats:p>The ongoing pandemic of Covid-19 caused by SARS-CoV-2 is a major threat to global public health, drawing attention to develop new therapeutics for treatment. Much research work is focused on identifying or repurposing new small molecules to serve as potential inhibitors by interacting with viral or host-cell molecular targets and understanding the nature of the virus in the host cells. Identifying small molecules as potent inhibitors at an early stage is advantageous in developing a molecule with higher potency and then finding a lead compound for the development of drug discovery. Small molecules can show their inhibition property by targeting either the SARS-CoV-2 main protease (Mpro) enzyme, papain-like protease (PLpro) enzyme, or helicase (Hel), or blocking the spike (S) protein angiotensin-converting enzyme 2 (ACE2) receptor. A very recent outbreak of a new variant (B.1.617.2\u2014termed as Delta variant) of SARS-CoV-2 worldwide posed a greater challenge as it is resistant to clinically undergoing vaccine trials. Thus, the development of new drug molecules is of potential interest to combat SARS-CoV-2 disease, and for that, the fragment-based drug discovery (FBDD) approach could be one of the ways to bring out an effective solution. Two cysteine protease enzymes would be an attractive choice of target for fragment-based drug discovery to tune the molecular structure at an early stage with suitable functionality. In this short review, the recent development in small molecules as inhibitors against Covid-19 is discussed, and the opportunity for FBDD is envisioned optimistically to provide an outlook regarding Covid-19 that may pave the way in the direction of the Covid-19 drug development paradigm.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573406418666220214091107","type":"journal-article","created":{"date-parts":[[2022,2,14]],"date-time":"2022-02-14T11:20:36Z","timestamp":1644837636000},"page":"847-858","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Recent Development in Small Molecules for SARS-CoV-2 and the Opportunity for Fragment-Based Drug Discovery"],"prefix":"10.2174","volume":"18","author":[{"given":"Sujit","family":"Mahato","sequence":"first","affiliation":[{"name":"Department of Chemistry, Sardar Vallabhbhai National Institute of Technology, Surat, Gujarat-395007, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","unstructured":"SARS-CoV-2 viral mutations: Impact on COVID-19 tests. Available from: (accessed on September 1, 2021)."},{"key":"ref=2","unstructured":"Delta variant: What we know about the science. Available from: (accessed on September 1, 2021)."},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","volume":"6","author":"Kyriakidis N.C.","year":"2021","unstructured":"Kyriakidis N.C.; L\u00f3pez-Cort\u00e9s A.; Gonz\u00e1lez E.V.; Gri-maldos A.B.; Prado E.O.; SARS-CoV-2 vaccines strategies: A comprehensive review of phase 3 candidates. NPJ. Vaccines (Basel) 2021,6(1),28-45","journal-title":"Vaccines (Basel)"},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1038\/s41586-020-2798-3","volume":"586","author":"Krammer F.","year":"2020","unstructured":"Krammer F.; SARS-CoV-2 vaccines in development. Nature 2020,586(7830),516-527","journal-title":"Nature"},{"key":"ref=b","doi-asserted-by":"crossref","unstructured":"Different COVID-19 vaccines. Available from: (accessed on September 2, 2021).","DOI":"10.26416\/Med.140.2.2021.4965"},{"key":"ref=4","unstructured":"Emergence of SARS-CoV-2 B.1.1.7. Lineage \u2013 United States. Morbidity and Mortality Weekly Report (MMWR). Available from: (accessed on September 2, 2021)."},{"key":"ref=5","unstructured":"How dangerous is the delta variant (B.1.617.2)? Available from: (accessed on September 2, 2021)."},{"key":"ref=b","unstructured":"What are the Covid variants and will vaccines still work? Available from: (accessed on September 2, 2021)."},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/s41586-021-03777-9","volume":"596","year":"2021","unstructured":"Planas, D.; Veyer, D.; Baidaliuk, A.; Staropoli, I.; Guivel- Benhassine, F.; Rajah, M.M.; Planchais, C.; Porrot, F.; Robillard, N.; Puech, J.; Prot, M.; Gallais, F.; Gantner, P.; Velay, A.; Le Guen, J.; Kassis-Chikhani, N.; Edriss, D.; Belec, L.; Seve, A.; Courtellemont, L.; P\u00e9r\u00e9, H.; Hocqueloux, L.; Fafi-Kremer, S.; Prazuck, T.; Mouquet, H.; Bruel, T.; Simon-Lori\u00e8re, E.; Rey, F.A.; Schwartz, O. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature 2021,596(7871),276-280","journal-title":"Nature"},{"key":"ref=6","unstructured":"Tracking SARS-CoV-2 variants. Available from: (accessed on September 2, 2021)."},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12859-018-2153-y","volume":"19","year":"2018","unstructured":"King, M.D.; Long, T.; Pfalmer, D.L.; Andersen, T.L.; McDougal, O.M. SPIDR: Small-molecule peptide-influenced drug repurposing. BMC bioinfo 2018,19(1),138-149","journal-title":"BMC bioinfo"},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1021\/acs.oprd.0c00233","volume":"24","year":"2020","unstructured":"Savi, C.D.; Hughes, D.L.; Kvaerno, L. Quest for a COVID-19 cure by repurposing small-molecule drugs: Mechanism of action, clinical development, synthesis at scale, and outlook for supply. Org Process Res Dev 2020,24(6),940-976","journal-title":"Org Process Res Dev"},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"e2024302118","DOI":"10.1073\/pnas.2024302118","volume":"118","author":"Jang W.D.","year":"2021","unstructured":"Jang W.D.; Jeon S.; Kim S.; Lee S.Y.; Drugs repurposed for COVID-19 by virtual screening of 6,218 drugs and cell-based assay. Proc Natl Acad Sci USA 2021,118(30),e2024302118","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","volume":"583","author":"Gordon D.E.","year":"2020","unstructured":"Gordon D.E.; Jang G.M.; Bouhaddou M.; Xu J.; Obernier K.; White K.M.; O\u2019Meara M.J.; Rezelj V.V.; Guo J.Z.; Swaney D.L.; Tummino T.A.; H\u00fcttenhain R.; Kaake R.M.; Richards A.L.; Tutuncuoglu B.; Foussard H.; Batra J.; Haas K.; Modak M.; Kim M.; Haas P.; Polacco B.J.; Braberg H.; Fabius J.M.; Eckhardt M.; Soucheray M.; Bennett M.J.; Cakir M.; McGregor M.J.; Li Q.; Meyer B.; Roesch F.; Val-let T.; Mac Kain A.; Miorin L.; Moreno E.; Naing Z.Z.C.; Zhou Y.; Peng S.; Shi Y.; Zhang Z.; Shen W.; Kirby I.T.; Melnyk J.E.; Chorba J.S.; Lou K.; Dai S.A.; Barrio-Hernandez I.; Memon D.; Hernandez-Armenta C.; Lyu J.; Mathy C.J.P.; Perica T.; Pilla K.B.; Ganesan S.J.; Saltzberg D.J.; Rakesh R.; Liu X.; Rosenthal S.B.; Calviello L.; Ven-kataramanan S.; Liboy-Lugo J.; Lin Y.; Huang X.P.; Liu Y.; Wankowicz S.A.; Bohn M.; Safari M.; Ugur F.S.; Koh C.; Savar N.S.; Tran Q.D.; Shengjuler D.; Fletcher S.J.; O\u2019Neal M.C.; Cai Y.; Chang J.C.J.; Broadhurst D.J.; Klipp-sten S.; Sharp P.P.; Wenzell N.A.; Kuzuoglu-Ozturk D.; Wang H.Y.; Trenker R.; Young J.M.; Cavero D.A.; Hiatt J.; Roth T.L.; Rathore U.; Subramanian A.; Noack J.; Hubert M.; Stroud R.M.; Frankel A.D.; Rosenberg O.S.; Verba K.A.; Agard D.A.; Ott M.; Emerman M.; Jura N.; von Zastrow M.; Verdin E.; Ashworth A.; Schwartz O.; d\u2019Enfert C.; Mukherjee S.; Jacobson M.; Malik H.S.; Fu-jimori D.G.; Ideker T.; Craik C.S.; Floor S.N.; Fraser J.S.; Gross J.D.; Sali A.; Roth B.L.; Ruggero D.; Taunton J.; Kortemme T.; Beltrao P.; Vignuzzi M.; Garc\u00eda-Sastre A.; Shokat K.M.; Shoichet B.K.; Krogan N.J.A.; SARS-CoV-2 protein interaction map reveals targets for drug repurposing. Nature 2020,583(7816),459-468","journal-title":"Nature"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/s41467-020-20768-y","volume":"12","author":"Lu S.","year":"2021","unstructured":"Lu S.; Ye Q.; Singh D.; Cao Y.; Diedrich J.K.; Yates J.R.; Villa E.; Cleveland D.W.; Corbett K.D.; The SARS-CoV-2 nucleocapsid phosphoprotein forms mutually exclusive condensates with RNA and the membrane-associated M pro-tein. Nat Commun 2021,12(1),502-517","journal-title":"Nat Commun"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"32725","DOI":"10.1074\/jbc.M109.043547","volume":"284","author":"Shulla A.","year":"2009","unstructured":"Shulla A.; Gallagher T.; Role of spike protein endodomains in regulating coronavirus entry. J Biol Chem 2009,284(47),32725-32734","journal-title":"J Biol Chem"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.3390\/v12111289","volume":"12","author":"Wang L.","year":"2020","unstructured":"Wang L.; Xiang Y.; Spike glycoprotein-mediated entry of SARS coronaviruses. Viruses 2020,12(11),1289-1302","journal-title":"Viruses"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"2590","DOI":"10.1016\/j.jmb.2018.06.024","volume":"430","author":"Maginnis M.S.","year":"2018","unstructured":"Maginnis M.S.; Virus-receptor interactions: The key to cellu-lar invasion. J Mol Biol 2018,430(17),2590-2611","journal-title":"J Mol Biol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"736511","DOI":"10.3389\/fphar.2021.736511","volume":"12","author":"Erukainure O.L.","year":"2021","unstructured":"Erukainure O.L.; Matsabisa M.G.; Muhammad A.; Abarshi M.M.; Amaku J.F.; Katsayal S.B.; Nde A.L.; Targeting of protein\u2019s messenger RNA for viral replication, assembly and release in SARS-CoV-2 using whole genomic data from South Africa: Therapeutic potentials of Cannabis sativa L. Front Pharmacol 2021,12,736511","journal-title":"Front Pharmacol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1099\/vir.0.19424-0","volume":"84","author":"Thiel V.","year":"2003","unstructured":"Thiel V.; Ivanov K.A.; Putics \u00c1.; Hertzig T.; Schelle B.; Bayer S.; Wei\u00dfbrich B.; Snijder E.J.; Rabenau H.; Doerr H.W.; Gorbalenya A.E.; Ziebuhr J.; Mechanisms and en-zymes involved in SARS coronavirus genome expression. J Gen Virol 2003,84(Pt 9),2305-2315","journal-title":"J Gen Virol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.mib.2004.06.007","volume":"7","author":"Ziebuhr J.","year":"2004","unstructured":"Ziebuhr J.; Molecular biology of severe acute respiratory syndrome coronavirus. Curr Opin Microbiol 2004,7(4),412-419","journal-title":"Curr Opin Microbiol"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1099\/0022-1317-81-4-853","volume":"81","author":"Ziebuhr J.","year":"2000","unstructured":"Ziebuhr J.; Snijder E.J.; Gorbalenya A.E.; Virus-encoded proteinases and proteolytic processing in the Nidovirales. J Gen Virol 2000,81(Pt 4),853-879","journal-title":"J Gen Virol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"33220","DOI":"10.1074\/jbc.M104097200","volume":"276","author":"Ziebuhr J.","year":"2001","unstructured":"Ziebuhr J.; Thiel V.; Gorbalenya A.E.; The autocatalytic release of a putative RNA virus transcription factor from its polyprotein precursor involves two paralogous papain-like proteases that cleave the same peptide bond. J Biol Chem 2001,276(35),33220-33232","journal-title":"J Biol Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.antiviral.2014.12.015","volume":"115","author":"B\u00e1ez-Santos Y.M.","year":"2015","unstructured":"B\u00e1ez-Santos Y.M.; St John S.E.; Mesecar A.D.; The SARS-coronavirus papain-like protease: Structure, function and in-hibition by designed antiviral compounds. Antiviral Res 2015,115,21-38","journal-title":"Antiviral Res"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.apsb.2020.02.008","volume":"10","author":"Wu C.","year":"2020","unstructured":"Wu C.; Liu Y.; Yang Y.; Zhang P.; Zhong W.; Wang Y.; Wang Q.; Xu Y.; Li M.; Li X.; Zheng M.; Chen L.; Li H.; Analysis of therapeutic targets for SARS-CoV-2 and discov-ery of potential drugs by computational methods. Acta Pharm Sin B 2020,10(5),766-788","journal-title":"Acta Pharm Sin B"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1038\/s41467-021-21060-3","volume":"12","author":"Osipiuk J.","year":"2021","unstructured":"Osipiuk J.; Azizi S.A.; Dvorkin S.; Endres M.; Jedrzejczak R.; Jones K.A.; Kang S.; Kathayat R.S.; Kim Y.; Lisnyak V.G.; Maki S.L.; Nicolaescu V.; Taylor C.A.; Tesar C.; Zhang Y.A.; Zhou Z.; Randall G.; Michalska K.; Snyder S.A.; Dickinson B.C.; Joachimiak A.; Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors. Nat Commun 2021,12(1),743-752","journal-title":"Nat Commun"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"645713","DOI":"10.3389\/fmicb.2021.645713","volume":"12","author":"Pendyala B.","year":"2021","unstructured":"Pendyala B.; Patras A.; Dash C.; Phycobilins as potent food bioactive broad-spectrum inhibitors against proteases of SARS-CoV-2 and other coronaviruses: A preliminary study. Front Microbiol 2021,12,645713","journal-title":"Front Microbiol"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.peptides.2004.06.018","volume":"25","author":"Du Q.S.","year":"2004","unstructured":"Du Q.S.; Wang S.Q.; Zhu Y.; Wei D.Q.; Guo H.; Sirois S.; Chou K.C.; Polyprotein cleavage mechanism of SARS CoV Mpro and chemical modification of the octapeptide. Peptides 2004,25(11),1857-1864","journal-title":"Peptides"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.jmb.2009.07.062","volume":"392","author":"Tian X.","year":"2009","unstructured":"Tian X.; Lu G.; Gao F.; Peng H.; Feng Y.; Ma G.; Bartlam M.; Tian K.; Yan J.; Hilgenfeld R.; Gao G.F.; Structure and cleavage specificity of the chymotrypsin-like serine protease (3CLSP\/nsp4) of Porcine Reproductive and Respiratory Syn-drome Virus (PRRSV). J Mol Biol 2009,392(4),977-993","journal-title":"J Mol Biol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"e200254","DOI":"10.1590\/0074-02760200254","volume":"115","author":"Senger M.R.","year":"2020","unstructured":"Senger M.R.; Evangelista T.C.S.; Dantas R.F.; Santana M.V.D.S.; Gon\u00e7alves L.C.S.; de Souza Neto L.R.; Ferreira S.B.; Silva-Junior F.P.; COVID-19: Molecular targets, drug re-purposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz 2020,115(e200254),e200254","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"11779322211025876","DOI":"10.1177\/11779322211025876","volume":"15","author":"Gorkhali R.","year":"2021","unstructured":"Gorkhali R.; Koirala P.; Rijal S.; Mainali A.; Baral A.; Bhat-tarai H.K.; Structure and function of major SARS-CoV-2 and SARS-CoV proteins. Bioinform Biol Insights 2021,15,11779322211025876","journal-title":"Bioinform Biol Insights"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"622898","DOI":"10.3389\/fchem.2021.622898","volume":"9","author":"Mengist H.M.","year":"2021","unstructured":"Mengist H.M.; Dilnessa T.; Jin T.; Structural basis of poten-tial inhibitors targeting SARS-CoV-2 main protease. Front Chem 2021,9,622898","journal-title":"Front Chem"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.apsb.2020.08.014","volume":"11","author":"Gaoa X.","year":"2021","unstructured":"Gaoa X.; Qin B.; Chen P.; Zhu K.; Hou P.; Wojdyla J.A.; Wang M.; Cui S.; Crystal structure of SARS-CoV-2 papain-like protease. Acta Pharm Sin B 2021,11(1),237-245","journal-title":"Acta Pharm Sin B"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"15189","DOI":"10.1128\/JVI.79.24.15189-15198.2005","volume":"79","author":"Barretto N.","year":"2005","unstructured":"Barretto N.; Jukneliene D.; Ratia K.; Chen Z.; Mesecar A.D.; Baker S.C.; The papain-like protease of severe acute respiratory syndrome coronavirus has deubiquitinating activi-ty. J Virol 2005,79(24),15189-15198","journal-title":"J Virol"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"111313","DOI":"10.1016\/j.biopha.2021.111313","volume":"137","author":"Tian D.","year":"2021","unstructured":"Tian D.; Liu Y.; Liang C.; Xin L.; Xie X.; Zhang D.; Wan M.; Li H.; Fu X.; Liu H.; Cao W.; An update review of emerging small-molecule therapeutic options for COVID-19. Biomed Pharmacother 2021,137,111313-111330","journal-title":"Biomed Pharmacother"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"7429","DOI":"10.1038\/s41598-021-86471-0","volume":"11","author":"Weng Y.L.","year":"2021","unstructured":"Weng Y.L.; Naik S.R.; Dingelstad N.; Lugo M.R.; Kal-yaanamoorthy S.; Ganesan A.; Molecular dynamics and in silico mutagenesis on the reversible inhibitor-bound SARS-CoV-2 main protease complexes reveal the role of lateral pocket in enhancing the ligand affinity. Sci Rep 2021,11(1),7429-7451","journal-title":"Sci Rep"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"3202","DOI":"10.1038\/s41467-020-16954-7","volume":"11","author":"Kneller D.W.","year":"2020","unstructured":"Kneller D.W.; Phillips G.; O\u2019Neill H.M.; Jedrzejczak R.; Stols L.; Langan P.; Joachimiak A.; Coates L.; Kovalevsky A.; Structural plasticity of SARS-CoV-2 3CL Mpro active site cavity revealed by room temperature X-ray crystallography. Nat Commun 2020,11(1),3202-3208","journal-title":"Nat Commun"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1093\/emboj\/cdf327","volume":"21","author":"Anand K.","year":"2002","unstructured":"Anand K.; Palm G.J.; Mesters J.R.; Siddell S.G.; Ziebuhr J.; Hilgenfeld R.; Structure of coronavirus main proteinase re-veals combination of a chymotrypsin fold with an extra","journal-title":"EMBO J"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"17365","DOI":"10.1074\/jbc.AC120.016154","volume":"295","author":"Kneller D.W.","year":"2020","unstructured":"Kneller D.W.; Phillips G.; Weiss K.L.; Pant S.; Zhang Q.; O\u2019Neill H.M.; Coates L.; Kovalevsky A.; Unusual zwitteri-onic catalytic site of SARS-CoV-2 main protease revealed by neutron crystallography. J Biol Chem 2020,295(50),17365-17373","journal-title":"J Biol Chem"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"5047","DOI":"10.1038\/s41467-020-18709-w","volume":"11","author":"Douangamath A.","year":"2020","unstructured":"Douangamath A.; Fearon D.; Gehrtz P.; Krojer T.; Lukacik P.; Owen C.D.; Resnick E.; Strain-Damerell C.; Aimon A.; \u00c1br\u00e1nyi-Balogh P.; Brand\u00e3o-Neto J.; Carbery A.; Davison G.; Dias A.; Downes T.D.; Dunnett L.; Fairhead M.; Firth J.D.; Jones S.P.; Keeley A.; Keser\u00fc G.M.; Klein H.F.; Mar-tin M.P.; Noble M.E.M.; O\u2019Brien P.; Powell A.; Reddi R.N.; Skyner R.; Snee M.; Waring M.J.; Wild C.; London N.; von Delft F.; Walsh M.A.; Crystallographic and electro-philic fragment screening of the SARS-CoV-2 main protease. Nat Commun 2020,11(1),5047-5058","journal-title":"Nat Commun"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"20918","DOI":"10.1038\/srep20918","volume":"6","author":"Li C.","year":"2016","unstructured":"Li C.; Teng X.; Qi Y.; Tang B.; Shi H.; Ma X.; Lai L.; Conformational flexibility of a short loop near the active site of the SARS-3CLpro is essential to maintain catalytic activity. Sci Rep 2016,6,20918-20927","journal-title":"Sci Rep"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1021\/acscombsci.0c00058","volume":"22","author":"Goyal B.","year":"2020","unstructured":"Goyal B.; Goyal D.; Targeting the dimerization of the main protease of coronaviruses: A potential broad-spectrum thera-peutic strategy. ACS Comb Sci 2020,22(6),297-305","journal-title":"ACS Comb Sci"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"6307457","DOI":"10.1155\/2020\/6307457","volume":"2020","author":"Tallei T.E.","year":"2020","unstructured":"Tallei T.E.; Tumilaar S.G.; Niode N.J.; Fatimawali; Kepel, B.J.; Idroes, R.; Effendi, Y.; Sakib, S.A.; Emran, T.B. Poten-tial of plant bioactive compounds as SARS-CoV-2 Main Pro-tease (Mpro) and Spike (S) glycoprotein inhibitors: A molecu-lar docking study. Scientifica (Cairo) 2020,2020,6307457","journal-title":"Scientifica (Cairo)"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"9121","DOI":"10.1039\/D0CS01065K","volume":"50","author":"Muratov E.N.","year":"2021","unstructured":"Muratov E.N.; Amaro R.; Andrade C.H.; Brown N.; Ekins S.; Fourches D.; Isayev O.; Kozakov D.; Medina-Franco J.L.; Merz K.M.; Oprea T.I.; Poroikov V.; Schneider G.; Todd M.H.; Varnek A.; Winkler D.A.; Zakharov A.V.; Cherkasov A.; Tropsha A.; A critical overview of computa-tional approaches employed for COVID-19 drug discovery. Chem Soc Rev 2021,50(16),9121-9151","journal-title":"Chem Soc Rev"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"129026","DOI":"10.1016\/j.molstruc.2020.129026","volume":"1224","author":"Ghosh K.","year":"2021","unstructured":"Ghosh K.; Amin S.A.; Gayen S.; Jha T.; Chemical-informatics approach to COVID-19 drug discovery: Explora-tion of important fragments and data mining based prediction of some hits from natural origins as main protease (Mpro) in-hibitors. J Mol Struct 2021,1224,129026","journal-title":"J Mol Struct"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"12359","DOI":"10.1021\/acs.jmedchem.0c00606","volume":"63","author":"Gil C.","year":"2020","unstructured":"Gil C.; Ginex T.; Maestro I.; Nozal V.; Barrado-Gil L.; Cuesta-Geijo M.\u00c1.; Urquiza J.; Ram\u00edrez D.; Alonso C.; Campillo N.E.; Martinez A.; COVID-19: Drug targets and po-tential treatments. J Med Chem 2020,63(21),12359-12386","journal-title":"J Med Chem"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s13337-021-00717-z","volume":"32","author":"Abdul-Hammed M.","year":"2021","unstructured":"Abdul-Hammed M.; Adedotun I.O.; Falade V.A.; Adepoju A.J.; Olasupo S.B.; Akinboade M.W.; Target-based drug dis-covery, ADMET profiling and bioactivity studies of antibiot-ics as potential inhibitors of SARS-CoV-2 main protease (Mpro). Virusdisease 2021,32,1-15","journal-title":"Virusdisease"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1021\/acs.jproteome.0c00526","volume":"20","author":"Zhang Y.","year":"2021","unstructured":"Zhang Y.; Tang L.V.; Overview of targets and potential drugs of SARS-CoV-2 according to the viral replication. J Proteome Res 2021,20(1),49-59","journal-title":"J Proteome Res"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"10423","DOI":"10.1002\/anie.202016961","volume":"60","author":"Breidenbach J.","year":"2021","unstructured":"Breidenbach J.; Lemke C.; Pillaiyar T.; Sch\u00e4kel L.; Al Hamwi G.; Diett M.; Gedschold R.; Geiger N.; Lopez V.; Mirza S.; Namasivayam V.; Schiedel A.C.; Sylvester K.; Thimm D.; Vielmuth C.; Phuong Vu L.; Zyulina M.; Bodem J.; G\u00fctschow M.; M\u00fcller C.E.; Targeting the main protease of SARS-CoV-2: From the establishment of high throughput screening to the design of tailored inhibitors. Angew Chem Int Ed Engl 2021,60(18),10423-10429","journal-title":"Angew Chem Int Ed Engl"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"115860","DOI":"10.1016\/j.bmc.2020.115860","volume":"29","author":"Amin S.A.","year":"2021","unstructured":"Amin S.A.; Banerjee S.; Ghosh K.; Gayen S.; Jha T.; Prote-ase targeted COVID-19 drug discovery and its challenges: In-sight into viral main protease (Mpro) and papain-like protease (PLpro) inhibitors. Bioorg Med Chem 2021,29,115860-115760","journal-title":"Bioorg Med Chem"},{"key":"ref=45","doi-asserted-by":"publisher","unstructured":"Erlanson, D.A.; Jahnke, W. The concept of fragment-based drug discovery. In: Fragment\u2010based Approaches in Drug Discovery; Jahnke, W.; Erlanson, D.A., Eds.; Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, 2006; pp. 1-9.","DOI":"10.1002\/3527608761.ch1"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrd.2016.109","volume":"15","author":"Erlanson D.A.","year":"2016","unstructured":"Erlanson D.A.; Fesik S.W.; Hubbard R.E.; Jahnke W.; Jhoti H.; Twenty years on: The impact of fragments on drug discov-ery. Nat Rev Drug Discov 2016,15(9),605-619","journal-title":"Nat Rev Drug Discov"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"180","DOI":"10.3389\/fmolb.2020.00180","volume":"7","author":"Li Q.","year":"2020","unstructured":"Li Q.; Application of fragment-based drug discovery to versa-tile targets. Front Mol Biosci 2020,7,180-193","journal-title":"Front Mol Biosci"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1021\/acs.jpclett.1c01064","volume":"12","author":"Bhattarai A.","year":"2021","unstructured":"Bhattarai A.; Pawnikar S.; Miao Y.; Mechanism of ligand recognition by human ACE2 receptor. J Phys Chem Lett 2021,12(20),4814-4822","journal-title":"J Phys Chem Lett"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/s41467-021-20900-6","volume":"12","author":"Hattori S.I.","year":"2021","unstructured":"Hattori S.I.; Higashi-Kuwata N.; Hayashi H.; Allu S.R.; Raghavaiah J.; Bulut H.; Das D.; Anson B.J.; Lendy E.K.; Takamatsu Y.; Takamune N.; Kishimoto N.; Murayama K.; Hasegawa K.; Li M.; Davis D.A.; Kodama E.N.; Yarchoan R.; Wlodawer A.; Misumi S.; Mesecar A.D.; Ghosh A.K.; Mitsuya H.; A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication. Nat Commun 2021,12(1),668-680","journal-title":"Nat Commun"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1038\/s41467-020-18096-2","volume":"11","author":"Vuong W.","year":"2020","unstructured":"Vuong W.; Khan M.B.; Fischer C.; Arutyunova E.; Lamer T.; Shields J.; Saffran H.A.; McKay R.T.; van Belkum M.J.; Joyce M.A.; Young H.S.; Tyrrell D.L.; Vederas J.C.; Lemieux M.J.; Feline coronavirus drug inhibits the main pro-tease of SARS-CoV-2 and blocks virus replication. Nat Commun 2020,11(1),4282-4290","journal-title":"Nat Commun"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1002\/cbic.202000047","volume":"21","author":"Morse J.S.","year":"2020","unstructured":"Morse J.S.; Lalonde T.; Xu S.; Liu W.R.; Learning from the past: Possible urgent prevention and treatment options for se-vere acute respiratory infections caused by 2019-nCoV. ChemBioChem 2020,21(5),730-738","journal-title":"ChemBioChem"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"e1005650","DOI":"10.1371\/journal.ppat.1005650","volume":"12","author":"Kim Y.","year":"2016","unstructured":"Kim Y.; Liu H.; Kankanamalage A.C.G.; Weerasekara S.; Hua D.H.; Groutas W.C.; Chang K.; Pedersen N.C.; Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor. PLoS Pathog 2016,12(5),e1005650","journal-title":"PLoS Pathog"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1021\/acsinfecdis.0c00168","volume":"6","author":"Freitas B.T.","year":"2020","unstructured":"Freitas B.T.; Durie I.A.; Murray J.; Longo J.E.; Miller H.C.; Crich D.; Hogan R.J.; Tripp R.A.; Pegan S.D.; Characteriza-tion and noncovalent inhibition of the deubiquitinase and de-ISGylase activity of SARS-CoV-2 papain-like protease. ACS Infect Dis 2020,6(8),2099-2109","journal-title":"ACS Infect Dis"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"12256","DOI":"10.1021\/acs.jmedchem.0c00502","volume":"63","author":"Xiu S.","year":"2020","unstructured":"Xiu S.; Dick A.; Ju H.; Mirzaie S.; Abdi F.; Cocklin S.; Zhan P.; Liu X.; Inhibitors of SARS-CoV-2 entry: Current and future opportunities. J Med Chem 2020,63(21),12256-12274","journal-title":"J Med Chem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"105998","DOI":"10.1016\/j.ijantimicag.2020.105998","volume":"56","author":"Vankadari N.","year":"2020","unstructured":"Vankadari N.; Arbidol: A potential antiviral drug for the treatment of SARS-CoV-2 by blocking trimerization of the spike glycoprotein. Int J Antimicrob Agents 2020,56(2),105998-106002","journal-title":"Int J Antimicrob Agents"},{"key":"ref=56","unstructured":"Efficacy of intravenous almitrine in reducing the need for mechanical ventilation in patients with hypoxemic acute respiratory failure due to Covid-19-related pneumonia (AIRVM-COVID). Available from: (accessed on September 25, 2021)."},{"key":"ref=b","unstructured":"Prediction of potential commercially inhibitors against SARSCoV-2 by multi-task deep model. Available from: (accessed on November 9, 2021)."},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/s41401-020-00556-6","volume":"42","author":"Yang L.","year":"2021","unstructured":"Yang L.; Pei R.J.; Li H.; Ma X.N.; Zhou Y.; Zhu F.H.; He P.L.; Tang W.; Zhang Y.C.; Xiong J.; Xiao S.Q.; Tong X.K.; Zhang B.; Zuo J.P.; Identification of SARS-CoV-2 entry inhibitors among already approved drugs. Acta Pharmacol Sin 2021,42(8),1347-1353","journal-title":"Acta Pharmacol Sin"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"3733","DOI":"10.1080\/07391102.2020.1771424","volume":"39","author":"Choudhury C.","year":"2021","unstructured":"Choudhury C.; Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease. J Biomol Struct Dyn 2021,39(10),3733-3746","journal-title":"J Biomol Struct Dyn"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"4745","DOI":"10.1021\/acs.jcim.1c00684","volume":"61","author":"Manandhar A.","year":"2021","unstructured":"Manandhar A.; Srinivasulu V.; Hamad M.; Tarazi H.; Omar H.; Colussi D.J.; Gordon J.; Childers W.; Klein M.L.; Al-Tel T.H.; Abou-Gharbia M.; Elokely K.M.; Discovery of novel small-molecule inhibitors of SARS-CoV-2 main prote-ase as potential leads for COVID-19 treatment. J Chem Inf Model 2021,61(9),4745-4757","journal-title":"J Chem Inf Model"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13578-021-00564-x","volume":"11","author":"Chen Z.","year":"2021","unstructured":"Chen Z.; Cui Q.; Cooper L.; Zhang P.; Lee H.; Chen Z.; Wang Y.; Liu X.; Rong L.; Du R.; Ginkgolic acid and ana-cardic acid are specific covalent inhibitors of SARS-CoV-2 cysteine proteases. Cell Biosci 2021,11(1),45-53","journal-title":"Cell Biosci"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"106114","DOI":"10.1016\/j.ijantimicag.2020.106114","volume":"56","author":"Tong S.","year":"2020","unstructured":"Tong S.; Su Y.; Yu Y.; Wu C.; Chen J.; Wang S.; Jiang J.; Ribavirin therapy for severe COVID-19: A retrospective co-hort study. Int J Antimicrob Agents 2020,56(3),106114-106119","journal-title":"Int J Antimicrob Agents"},{"key":"ref=62","doi-asserted-by":"publisher","DOI":"10.1016\/j.apsb.2021.06.016","author":"Xiang R.","year":"2021","unstructured":"Xiang R.; Yu Z.; Wang Y.; Wang L.; Huo S.; Li Y.; Liang R.; Hao Q.; Ying T.; Gao Y.; Yu F.; Jiang S.; Recent ad-vances in developing small-molecule inhibitors against SARS-CoV-2. Acta Pharm Sin B in press2021","journal-title":"Acta Pharm Sin B"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","volume":"11","author":"Hassanipour S.","year":"2021","unstructured":"Hassanipour S.; Arab-Zozani M.; Amani B.; Heidarzad F.; Fathalipour M.; Martinez-de-Hoyo R.; The efficacy and safe-ty of Favipiravir in treatment of COVID-19: A systematic re-view and meta-analysis of clinical trials. Sci Rep 2021,11(1),11022-11033","journal-title":"Sci Rep"},{"key":"ref=64","unstructured":"Efficacy and safety of molnupiravir (MK-4482) in hospitalized adult participants with COVID-19 (MK-4482-001). Available from: (accessed on September 25, 2021)."},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41594-020-0440-6","volume":"27","author":"Jin Z.","year":"2020","unstructured":"Jin Z.; Zhao Y.; Sun Y.; Zhang B.; Wang H.; Wu Y.; Zhu Y.; Zhu C.; Hu T.; Du X.; Duan Y.; Yu J.; Yang X.; Yang X.; Yang K.; Liu X.; Guddat L.W.; Xiao G.; Zhang L.; Yang H.; Rao Z.; Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur. Nat Struct Mol Biol 2020,27(6),529-532","journal-title":"Nat Struct Mol Biol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1038\/s41586-020-2577-1","volume":"586","author":"Riva L.","year":"2020","unstructured":"Riva L.; Yuan S.; Yin X.; Martin-Sancho L.; Matsunaga N.; Pache L.; Burgstaller-Muehlbacher S.; De Jesus P.D.; Teriete P.; Hull M.V.; Chang M.W.; Chan J.F-W.; Cao J.; Poon V.K-M.; Herbert K.M.; Cheng K.; Nguyen T.H.; Rubanov A.; Pu Y.; Nguyen C.; Choi A.; Rathnasinghe R.; Schotsaert M.; Miorin L.; Dejosez M.; Zwaka T.P.; Sit K.Y.; Martinez-Sobrido L.; Liu W.C.; White K.M.; Chap-man M.E.; Lendy E.K.; Glynne R.J.; Albrecht R.; Ruppin E.; Mesecar A.D.; Johnson J.R.; Benner C.; Sun R.; Schultz P.G.; Su A.I.; Garc\u00eda-Sastre A.; Chatterjee A.K.; Yuen K.Y.; Chanda S.K.; Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 2020,586(7827),113-119","journal-title":"Nature"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/s41392-021-00653-w","volume":"6","author":"Zhang Q.","year":"2021","unstructured":"Zhang Q.; Xiang R.; Huo S.; Zhou Y.; Jiang S.; Wang Q.; Yu F.; Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct Target Ther 2021,6(1),233-252","journal-title":"Signal Transduct Target Ther"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1080\/07391102.2020.1760136","volume":"39","author":"Enmozhi S.K.","year":"2021","unstructured":"Enmozhi S.K.; Raja K.; Sebastine I.; Joseph J.; Andro-grapholide as a potential inhibitor of SARS-CoV-2 main pro-tease: An in silico approach. J Biomol Struct Dyn 2021,39(9),3092-3098","journal-title":"J Biomol Struct Dyn"},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1934578X211016610","volume":"16","year":"2021","unstructured":"Lim, X.Y.; Chan, J.S.W.; Tan, T.Y.C.; Teh, B.P.; Razak, M.R.M.A.; Mohamad, S.; Mohamed, A.F.S. Andrographis paniculata (Burm. F.) Wall. Ex Nees, andrographolide, and andrographolide analogues as SARS-CoV-2 antivirals? A Rapid Review. Nat Prod Commun 2021,16(5),1-15","journal-title":"Nat Prod Commun"},{"key":"ref=b","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.bbrc.2020.08.086","volume":"533","author":"Shi T.H.","year":"2020","unstructured":"Shi T.H.; Huang Y.L.; Chen C.C.; Pi W.C.; Hsu Y-L.; Lo L.C.; Chen W.Y.; Fu S.L.; Lin C.H.; Andro-grapholide and its fluorescent derivative inhibit the main pro-teases of 2019-nCoV and SARS-CoV through covalent link-age. Biochem Biophys Res Commun 2020,533(3),467-473","journal-title":"Biochem Biophys Res Commun"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"5877","DOI":"10.1038\/s41467-020-19662-4","volume":"11","author":"Lee J.","year":"2020","unstructured":"Lee J.; Worrall L.J.; Vuckovic M.; Rosell F.I.; Gentile F.; Ton A-T.; Caveney N.A.; Ban F.; Cherkasov A.; Paetzel M.; Strynadka N.C.J.; Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site. Nat Commun 2020,11(1),5877-5886","journal-title":"Nat Commun"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1021\/acsinfecdis.0c00874","volume":"7","author":"Namchuk M.N.","year":"2021","unstructured":"Namchuk M.N.; Early returns on small molecule therapeutics for SARS-CoV-2. ACS Infect Dis 2021,7(6),1298-1302","journal-title":"ACS Infect Dis"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"5048","DOI":"10.1038\/s41467-020-18710-3","volume":"11","author":"Erlanson D.A.","year":"2020","unstructured":"Erlanson D.A.; Many small steps towards a COVID-19 drug. Nat Commun 2020,11(1),5048-5052","journal-title":"Nat Commun"},{"key":"ref=72","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10858-020-00327-9","volume":"74","author":"Sreeramulu S.","year":"2020","unstructured":"Sreeramulu S.; Richter C.; Kuehn T.; Azzaoui K.; Blom-mers M.J.J.; Del Conte R.; Fragai M.; Trieloff N.; Schmied-er P.; Nazar\u00e9 M.; Specker E.; Ivanov V.; Oschkinat H.; Banci L.; Schwalbe H.; NMR quality control of fragment li-braries for screening. J Biomol NMR 2020,74(10-11),555-563","journal-title":"J Biomol NMR"},{"key":"ref=73","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/cbdd.13914","volume":"98","author":"Ahmad S.","year":"2021","unstructured":"Ahmad S.; Usman Mirza M.; Yean Kee L.; Nazir M.; Abdul Rahman N.; Trant J.F.; Abdullah I.; Fragment-based in silico design of SARS-CoV-2 main protease inhibitors. Chem Biol Drug Des 2021,98(4),604-619","journal-title":"Chem Biol Drug Des"},{"key":"ref=74","doi-asserted-by":"publisher","first-page":"130366","DOI":"10.1016\/j.molstruc.2021.130366","volume":"1237","author":"Ghosh K.","year":"2021","unstructured":"Ghosh K.; Amin S.A.; Gayen S.; Jha T.; Unmasking of cru-cial structural fragments for coronavirus protease inhibitors and its implications in COVID-19 drug discovery. J Mol Struct 2021,1237,130366-130377","journal-title":"J Mol Struct"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","volume":"582","author":"Jin Z.","year":"2020","unstructured":"Jin Z.; Du X.; Xu Y.; Deng Y.; Liu M.; Zhao Y.; Zhang B.; Li X.; Zhang L.; Peng C.; Duan Y.; Yu J.; Wang L.; Yang K.; Liu F.; Jiang R.; Yang X.; You T.; Liu X.; Yang X.; Bai F.; Liu H.; Liu X.; Guddat L.W.; Xu W.; Xiao G.; Qin C.; Shi Z.; Jiang H.; Rao Z.; Yang H.; Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors. Nature 2020,582(7811),289-293","journal-title":"Nature"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s43141-021-00152-z","volume":"19","author":"Hossain M.U.","year":"2021","unstructured":"Hossain M.U.; Bhattacharjee A.; Emon M.T.H.; Chow-dhury Z.M.; Ahammad I.; Mosaib M.G.; Moniruzzaman M.; Rahman M.H.; Islam M.N.; Ahmed I.; Amin M.R.; Rashed A.; Das K.C.; Keya C.A.; Salimullah M.; Novel mu-tations in NSP-1 and PLPro of SARS-CoV-2 NIB-1 genome mount for effective therapeutics. J Genet Eng Biotechnol 2021,19(1),52-62","journal-title":"J Genet Eng Biotechnol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"e62414","DOI":"10.3791\/62414","volume":"171","author":"Douangamath A.","year":"2021","unstructured":"Douangamath A.; Powell A.; Fearon D.; Collins P.M.; Tal-on R.; Krojer T.; Skyner R.; Brandao-Neto J.; Dunnett L.; Dias A.; Aimon A.; Pearce N.M.; Wild C.; Gorrie-Stone T.; von Delft F.; Achieving efficient fragment screening at XChem facility at diamond light source. J Vis Exp 2021,171(171),e62414","journal-title":"J Vis Exp"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.ddtec.2010.12.001","volume":"7","author":"Edink E.","year":"2010","unstructured":"Edink E.; Jansen C.; Leurs R.; Esch I.J.P.; The heat is on: Thermodynamic analysis in fragment-based drug discovery. Drug Discov Today Technol 2010,7(3),e147-e202","journal-title":"Drug Discov Today Technol"}],"container-title":["Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220214091107","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/201085\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/1573406418666220214091107","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:47:53Z","timestamp":1700225273000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/201085\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":87,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573406418666220214091107","relation":{},"ISSN":["1573-4064"],"issn-type":[{"value":"1573-4064","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2021-10-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-11-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}